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Where Are We Now?
There are several ways to measuretreatment effects in orthopaedics.For example, arthroplasty regis-
tries traditionally consider the survival of
the implant as the primary outcome [6].
In clinical trials, on the other hand,
clinical scores such as the original Knee
Society Score or the Hospital for Special
Surgery scoring system are commonly
used. Unfortunately, clinical scores
might not always capture a patient’s
perception of his or her overall func-
tional status, quality of life, and/or pain.
In addition, many clinical scores require
a physical examination, resulting in in-
creased logistical burden and the possi-
bility of observer bias. For these reasons,
patient-reported outcome measures
(PROMs), such as the Oxford Knee
Score (OKS), have gained considerable
attention [4].
Selecting an outcome measure is
critically important when designing
a clinical trial. For example, if a re-
searcher chooses an outcome measure
that is not responsive to clinical change,
it is unlikely that such as study will
identify treatment effects, even if the
treatment delivers a “real” effect and the
study design is otherwise perfect. An
outcome measure should assess end-
points that matter most to patients, and it
should be sufﬁciently deﬁned so that it
can be used by other researchers. In ad-
dition, robust outcomes tools should be
well tested beforehand (unpublished and
unvalidated outcome measures are as-
sociated with bias [8]), reliable (that is, it
measures what it claims tomeasure), and
reproducible so that there are no varia-
tions upon retesting [8].
These requirements might appear
self-evident. However, there are
examples of studies published in high-
impact general medical journals where
the disease-speciﬁc primary outcome
was not validated [9] and even the
algorithm for the calculation of the
outcome was incomplete. It is not as-
tonishing that such a study fails to de-
tect differences between treatment
groups [9]. Nevertheless, the study
results inﬂuenced the recom-
mendations of an important clinical
practice guideline in orthopaedic sur-
gery [11].
There are several PROMs to choose
from when assessing knee osteoar-
thritis before and after arthroplasty.
For example, both the WOMAC and
the OKS are disease-speciﬁc instru-
ments commonly used for the assess-
ment of patients with osteoarthritis of
the knee, and these instruments are
considered reliable and reproducible.
Although developed in English-
speaking countries, several validated
translated versions of these instru-
ments are available in French, Spanish,
and German.
Where Do We Need To Go?
Because of the increasing interna-
tionalization of clinical trials [12] and
the large population in China, it would
be advantageous if the results of TKA
in China could be assessed by similar
outcome measures that are used in
Western countries. The authors of the
current study strive to ﬁll this gap. In
their paper, Lin and colleagues trans-
late and cross-culturally adapt the OKS
to a Chinese (Mandarin) version and
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calculate various psychometric prop-
erties for that score.
The Chinese version of the OKS
could be considered a validated outcome
instrument and can perhaps be used for
assessing Mandarin-speaking patients
undergoing TKA in China. However, as
the current study validated the Chinese
version of the OKS in terms of semantic
equivalence and psychometric proper-
ties, it is not clear if it is appropriate to
combine data collected by the Chinese
version of the OKS with data collected
by the original or other validated ver-
sions of OKS. Analyzing such mea-
surement equivalence is important, since
the assessment of differences among the
outcome measures might be difﬁcult to
detect, thereby leading to misleading
results and invalid ﬁndings [12].
The selection of the outcomemeasure
inﬂuences the result of clinical compar-
ative trials, and thereby inﬂuences treat-
ment decisions. For example, it is
possible, that a comparative randomized
trialmight demonstrate differenceswhen
outcome measure A is used, but no dif-
ferences when outcome measure B is
used. For this reason, it is mandatory that
the primary outcome measure be se-
lected in advance [8].
The Outcome Measures in Rheu-
matology Clinical Trials III Confer-
ence [2], which was ratiﬁed by the
Osteoarthritis Research Society In-
ternational Initiative (OARSI) Task
Force [1] recommends using a core set
of PROMS in osteoarthritis trials:
Physical function, pain, and patient
global assessment.
Currently, there is no clear recom-
mendation as to which outcome mea-
sure speciﬁcally should be used in
clinical trials of TKA. There are rea-
sons, though, why joint-speciﬁc scales
should be used, and that disease-
speciﬁc tools alone are insufﬁcient.
For example, the OKS has been spe-
ciﬁcally developed to be “joint-speciﬁc
in order to increase their sensitivity to
the outcome of the joint replacement as
far as possible and to be inﬂuenced as
little as possible by other comorbid-
ities” [10]. The OKS returns a single
score result, in which both the pain
dimension and the function dimension
are included, as can be seen in the ex-
planatory factor analysis presented by
Lin as well. On the other hand, the
WOMAC—a disease-speciﬁc tool for
patients with osteoarthritis of the hip or
knee, but not a joint-speciﬁc scale—was
not designed initially to evaluate out-
comes from total hip or total knee re-
placement, but it is commonly used for
that purpose. The WOMAC returns four
score results, one for each of the three
subscores pain, function, and stiffness,
and one for the overall score. Therefore,
it might appear that the WOMAC is
more appropriate to meet the recom-
mendation of the OARSI. However, it
has recently been demonstrated that the
WOMAC “pain and function items that
asked about the same activity consis-
tently loaded on the same factor rather
than on separate pain and function fac-
tors” [5]. Therefore, the strict differenti-
ation between pain and function that is
suggested when analyzing the pain and
function subscores of the WOMAC has
been questioned [5].
Determining which instrument to
use depends on various factors, such as
the setting of the research project. For
example, national arthroplasty regis-
tries that aim to analyze PROMs in
thousands of patients have different
outcome selection criteria than ini-
tiators of randomized controlled trials.
How Do We Get There?
In order to compare the results of joint
replacement surgery, standardization of
the outcome measures is the key to
success. The current study is important
in this aspect, as it is the ﬁrst step to
implementing a validated Chinese ver-
sion of the OKS that compares the suc-
cess of knee replacement surgery in
mainland China to other countries with
different cultures.
Future studies, therefore, should
assess whether there is measurement
equivalence when comparing the Chi-
nese version with the original version
of the OKS. Measurement equivalence
has been deﬁned as present if “different
language versions of a HRQoL in-
strument would yield similar scores at
item and scale levels for respondents
with identical levels of health-related
quality of life” [7]. Several methods on
how to assess measurement equiva-
lence have also been discussed [12].
Although there is no gold standard
on the horizon regarding the outcomes
assessment of joint replacement sur-
gery, it would be advantageous if clear
recommendations were developed as
to which outcome measure should be
assessed in orthopaedic clinical trials,
depending on the study design and
other factors. These recommendations
should be developed by expert panels in
orthopaedics, speciﬁcally joint re-
placement surgery. We must reconsider
the current trend of over-representing
these panels with specialists who hardly
ever see patients undergoing joint re-
placement surgery, such as epidemiol-
ogists, methodologists, internists,
methods editors, patient representatives,
health research methodologists, and
biostatisticians [3, 11]. Once a recom-
mendation has been developed, it
should be published in scientiﬁc jour-
nals, mentioned in editorials, discussed
among orthopaedic societies, and added
to information for authors’ guidelines.
Furthermore, the administrators of
www.clinicaltrials.gov could be asked
to display a pop-up window showing
information regarding the
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recommended outcome measures as
soon as a joint replacement randomized
clinical trial is registered.
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